Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

Therapeutics and Clinical Risk Management

Volumn 4, Issue 4, 2008, Pages 713-720

  Deberdt, Walter ^a,c   Lipkovich, Ilya ^b   Heinloth, Alexandra N ^c   Liu, Lin ^b   Kollack Walker, Sara ^b   Edwards, Sara E ^b   Hoffmann, Vicki Poole ^b   Hardy, Thomas A ^b  

^a Eli Lilly Benelux   (Belgium)

^b ELI LILLY AND COMPANY   (United States)

^c NONE   (Belgium)

Author keywords

Antipsychotic switching; BMI; Discontinuation; Relapse; Weight

Indexed keywords

AMANTADINE; METFORMIN; OLANZAPINE; QUETIAPINE;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC PARAMETERS; MULTICENTER STUDY; OBESITY; PARANOIA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SYMPTOM; VITAL SIGN; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 52949147771     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ascher-Svanum H, Zhu B, Faries D, et al. 2006. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry, 6:8.
2. Baptista T, Rangel N, Fernandez V, et al. 2007. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial. Schizophr Res, 93:99-108.
3. Beasley CM Jr, Stauffer VL, Liu-Seifert H, et al. 2007. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol, 27:252-8.
4. Cramer JA, Rosenheck R. 1998. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv, 49:196-201.
5. Deberdt W, Winokur A, Cavazzoni PA, et al. 2005. Amantadine for weight gain associated with olanzapme treatment. Eur Neuropsychopharmacol, 15:13-21.
6. Essock SM, Covell NH, Davis SM, et al. 2006. Effectiveness of switching antipsychotic medications. Am J Psychiatry, 163:2090-5.
7. Garman PM, Ried LD, Bengtson MA, et al. 2007. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc (Wash), 47:373-8.
8. Gupta S, Masand PS, Virk S, et al. 2004. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res, 70:57-62.
9. Guy W. 1976. ECDEU Assessment manual for Psychopharmacology, Revised (Publication ADM 76-338). US Dept of Health, Education, and Welfare.
10. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 13:261-76.
11. Kinon BJ, Kaiser CJ, Ahmed S, et al. 2005. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol, 25:255-8.
12. Liu-Seifert H, Adams DH, Kinon BJ. 2005. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med, 3:21.
13. Mallinckrodt CH, Sanger TM, Dube S, et al. 2003. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry, 53:754-60.
14. Montes JM, Rodriguez JL, Balbo E, et al. 2007. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry, 31:383-8.
15. Perkins DO, Gu H, Weiden PJ, et al. 2007. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, of schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry, e1-e8 [Epub ahead of print].
16. Stroup TS, Lieberman JA, McEvoy JP, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry, 163:611-22.
17. Weiden PJ, Kozma C, Grogg A, et al. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv, 55:886-91.